Meet Project ALS' Newest Researcher
06 December 2017
Meet Ghazeleh Sadri-Vakili, PhD, one of Project ALS’s newest researchers. Dr. Sadri-Vakili is a young, talented neuroscientist whose mentor is Rudolph Tanzi, a foremost Alzheimer’s investigator at Harvard Medical School. Dr. Sadri-Vakili recently opened her own lab at the Massachusetts General East Campus/Harvard Medical School. The Sadri-Vakili Lab is interested in identifying common pathways across neurodegenerative diseases, with a particular focus on ALS. Currently, and in collaboration with the Tanzi Lab, Dr. Sadri-Vakili is using drugs to target neuroinflammation and innate immunity pathways. Her lead ALS drug is cromolyn sodium, which was originally marketed to treat asthma. Based on data generated by the Tanzi Lab, Dr. Sadri-Vakili is aggressively testing whether cromolyn sodium extends survival in ALS mice, and confer neuroprotection in an array of cell-based models of ALS. One of the big pros of this drug is its delivery: through an inhaler.